Our Scientific Advisory Board is comprised of scientists who provide specific expertise on a consulting basis. The Board assists us on issues related to fundamental technologies, product development, potential applications and clinical testing.

 

Dr. Andrianov joined the Company in September 2006 as the Vice President of Research and Development. Dr. Andrianov brings over 20 years experience in the application of polymers as biomaterials and drug delivery systems. Most recently, he was the founder and Chief Scientific Officer of Parallel Solutions, Inc. from 2001 until 2005, where he developed biodegradable polymers for protein delivery and discovered a new class of potent vaccine immunoadjuvants. Prior to starting Parallel, he worked for Physical Science, Inc. as Principal Research Scientist and at Avant Immuonotherapeutics, Inc. as Director of Polymer Synthesis and Formulation. Dr. Andrianov is listed as an inventor on over 35 patents and patent applications and has published numerous technical papers. Dr. Andrianov received his Ph.D. in Polymer Science from Moscow State University in 1985 and served as a faculty member until 1991. He continued his academic training at the Massachusetts Institute of Technology.

 

Dr. Anderson practices dermatology at Massachusetts General Hospital and is the Director of the Wellman Center for Photomedicine at Massachusetts General Hospital. In addition, Dr. Anderson is a Professor of Dermatology at Harvard Medical School and is an affiliated faculty member at the Massachusetts Institute of Technology (MIT). Dr. Anderson has conceived and developed dermatologic surgery using selectively-absorbed laser pulses, which is now the preferred basis for treatment of birthmarks, pigmented lesions, tattoos, hypertrichosis and other conditions. Dr. Anderson received his undergraduate degree from MIT and his M.D. from Harvard Medical School.

 

Dr. Prausnitz's research interests concern microneedles and other microfabricated devices for drug delivery across the skin and into the eye, as well as novel uses of ultrasound and related physical phenomena to enhance and target intracellular delivery. Dr. Prausnitz received the CAREER Young Investigator Award from the National Science Foundation; Young Investigator Award, Outstanding Pharmaceutical Paper Award and Outstanding Transdermal Drug Delivery Award from the Controlled Release Society; Curtis W. McGraw Research Award from the American Society for Engineering Education; and TR100 Young Innovator from Technology Review. Dr. Prausnitz has a B.S. (1988) from Stanford University and a Ph.D. (1994) from Massachusetts Institute of Technology. He has published more than 80 research articles, holds 15 issued or pending patents, consults for a number of companies, and serves as an expert witness.

 

Hans Wigzell, a Professor of Immunology at Karolinska Institutet (Sweden), also serves as a Chief Scientific Advisor to the Swedish Government and is on the scientific advisory boards of several biotechnology companies. Professor Wigzell previously served as President of the Karolinska Institutet (1995-2003), Chairman of the Nobel Committee (1990-1992), and a Chairman of the Nobel Assembly (2000). His previous affiliations have also included positions as Chairman of the WHO-UNAIDS Vaccine Advisory Committee, Secretary-General of the Swedish Institute for Infectious Disease Control, and Director General of the National Bacteriological Laboratory in Stockholm. Professor Wigzell, who holds both M.D. and D.Sc. degrees, is an elected member of the Royal Swedish Academy of Sciences, the Royal Swedish Academy of Engineering Sciences, the Finnish Society of Sciences and Letters, the Danish Academy of Sciences and Letters, EMBO, and Academia Europea. In addition, Professor Wigzell is an honorary member of the American Society for Immunology, has received numerous awards, published over 600 articles and is a member of the editorial boards of several international journals.